Addition of Selinexor to Bortezomib, Dexamethasone Improves Responses in Myeloma

The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma.

Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Beth Fand Incollingo Source Type: news